Incidence of second primary cancers after radiotherapy combined with platinum and/or cetuximab in head and neck cancer patients
Olgun Eliçin(University of Bern), Daniel M. Aebersold(University of Bern), Burim Sermaxhaj(University of Bern), Mohamed Shelan(University of Bern), Daniel Rauch(Washington University in St. Louis), Roland Giger(University of Bern), Beat Bojaxhiu(University of Bern)
Cited by 9
Related Papers
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial
|The Lancet|2015|392
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
|The Lancet Respiratory Medicine|2017|184
Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29)
|Annals of Oncology|2016|140